MedTrace Logo

Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine

NCT03687905 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-09-27

No results posted yet for this study

Summary

Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of proliferative lupus nephritis class III and IV in children and adolescents and evaluate the side effects of both drugs .

Conditions

  • Proliferative Nephritis
  • Chloroquine Retinopathy

Interventions

DRUG

Chloroquine

group1 received chloroquine .

DRUG

Hydroxychloroquine

Group 2 received hydroxychloroquine

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Fatma S Gheet, M.B.,BCh · Tanta University

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-18
Primary Completion
2019-03-31
Completion
2019-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03687905 on ClinicalTrials.gov